Dec 21 |
Resveratrol for COVID-19: real-time meta analysis of 3 studies | |
Meta analysis using the most serious outcome reported shows 44% [-4‑70%] lower risk, without reaching statistical significance. Results are similar for Randomized Controlled Trials and better for peer-reviewed studies. Results .. | ||
Aug 3 2023 |
et al., Frontiers in Nutrition, doi:10.3389/fnut.2023.1241016 | Association of dietary intake of polyphenols, lignans, and phytosterols with immune-stimulating microbiota and COVID-19 risk in a group of Polish men and women |
Dietary analysis of 95 adults in Poland, showing lower risk of COVID-19 with higher intake of polyphenols, lignans, and phytosterols. Results were statistically significant for total phytosterols, secoisolariciresinol, β-sitosterol, matai.. | ||
Jun 29 2022 |
et al., Scientific Reports, doi:10.1038/s41598-022-13920-9 | Randomized double-blind placebo-controlled proof-of-concept trial of resveratrol for outpatient treatment of mild coronavirus disease (COVID-19) |
67% lower hospitalization (p=0.62) and 43% lower progression (p=0.52). RCT 100 outpatients in the USA, showing lower hospitalization and progression with resveratrol, without statistical significance. | ||
Mar 22 2022 |
et al., COVID, doi:10.3390/covid2040031 | A Randomised, Double-Blind, Placebo-Controlled Trial Evaluating Concentrated Phytochemical-Rich Nutritional Capsule in Addition to a Probiotic Capsule on Clinical Outcomes among Individuals with COVID-19—The UK Phyto-V Study |
44% greater improvement (p=0.02). RCT 147 long COVID patients in the UK, 56 treated with a phytochemical-rich concentrated food capsule, showing improved recovery with treatment. Treatment included curcumin, bioflavonoids, chamomile, ellagic acid, and resveratrol. | ||
Jan 21 2022 |
et al., European Journal of Microbiology and Immunology, doi:10.1556/1886.2021.00022 | Inhibitory effects of specific combination of natural compounds against SARS-CoV-2 and its Alpha, Beta, Gamma, Delta, Kappa, and Mu variants |
In Vitro study testing combinations of plant extracts and micronutrients with several variants of SARS-CoV-2. A combination of vitamin C, N-acetylcysteine, curcumin, quercetin, resveratrol, theaflavin, naringenin, baicalin, and broccoli e.. | ||
Nov 14 2021 |
et al., Food Chemistry, doi:10.1016/j.foodchem.2021.131594 | Inhibition of the SARS-CoV-2 3CLpro main protease by plant polyphenols |
In Silico and In Vitro study of plant polyphenols identifying quercetin, curcumin, ellagic acid, epigallocatechin gallate, and resveratrol as SARS-CoV-2 3CLpro inhibitors with IC50 between 11.8µM and 23.4µM. Real-time binding was analyzed.. | ||
Oct 25 2021 |
et al., International Journal of Environmental Research and Public Health, doi:10.3390/ijerph19031172 (date from preprint) | Effect of a Nutritional Support System to Increase Survival and Reduce Mortality in Patients with COVID-19 in Stage III and Comorbidities: A Blinded Randomized Controlled Clinical Trial |
86% lower mortality (p=0.03) and 57% lower ventilation (p=0.31). 80 patient RCT with 40 patients treated with a comprehensive regimen of nutritional support, showing significantly lower mortality with treatment. Treatment contained cholecalciferol, vitamin C, zinc, spirulina maxima, folic acid, glutami.. | ||
Oct 11 2021 |
et al., Evidence-Based Complementary and Alternative Medicine, doi:10.1155/2021/8447545 | A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of a Nutritional Supplement (ImmuActive) for COVID-19 Patients |
43% improved recovery (p=0.004) and 6% faster viral clearance (p=0.47). RCT 100 patients in India, 50 treated with ImmuActive (curcumin, andrographolides, resveratrol, zinc, selenium, and piperine), showing improved recovery with treatment. | ||
Oct 1 2021 |
et al., SSRN, doi:10.2139/ssrn.3934228 | Resveratrol and Zinc in the Treatment of Outpatients With COVID-19 – The Reszinate Study - A Phase 1/2 Randomized Clinical Trial Utilizing Home Patient-Obtained Nasal and Saliva Viral Sampling |
14% higher ventilation (p=1), 14% higher ICU admission (p=1), and 14% higher hospitalization (p=1). Small RCT of zinc plus resveratrol in COVID-19+ outpatients, showing no significant differences in viral clearance or symptoms. Although the treatment group was older (46.3 vs. 38.5) and had more severe baseline symptoms, they had similar.. | ||
Jul 29 2020 |
et al., medRxiv, doi:10.1101/2020.07.21.20151423 | Resveratrol and Copper for treatment of severe COVID-19: an observational study (RESCU 002) |
44% lower mortality (p=0.06). Retrospective 230 severe COVID-19 patients in India, showing lower mortality with resveratrol + copper, without statistical significance. This study followed preclinical data showing that sepsis-related cytokine storm and fatality in mice.. | ||
Jun 4 2020 |
, P., Cell Stress and Chaperones, doi:10.1007/s12192-020-01126-9 | COVID-19 and heme oxygenase: novel insight into the disease and potential therapies |
Proposal that COVID-19 risk is related to low intracellular heme oxygenase (HO-1), and that therapies that raise HO-1 may be beneficial, which includes fluvoxamine, certain anesthetics (sevoflurane or isoflurane), hemin, estrogen, statins.. |
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.